Roche’s Genentech plans to start its Phase 3 this quarter, but primary completion will happen by 2028. Click here to find out ...
The Chosun Ilbo on MSN
Roche's CT-388 achieves 22.5% weight loss in phase 2
Roche, a Swiss pharmaceutical company, reported on the 27th, local time, that its obesity treatment pipeline ‘CT-388’ ...
18h
New fat jab that ‘slashes 22% of body weight in less than a year’ set to rival Mounjaro and Wegovy
A NEW jab set to rival the likes of Mounjaro and Wegovy helped people lose up to 22 per cent of their body weight in less ...
3h
ASEAN should adhere to rule of law in face of ‘unilateral actions,’ Philippines’ top diplomat says
Philippine Foreign Secretary Theresa Lazaro says Southeast Asian countries should steadfastly maintain restraint and adhere to international law as acts of aggression across Asia and “unilateral ...
Some lawmakers in the West Virginia Senate want to put copies of the first Bible printed in revolutionary America in certain ...
Some lawmakers in the West Virginia Senate want to put copies of the first Bible printed in revolutionary America in certain classrooms, but an effort by others to amend the bill to include the ...
Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...
Some lawmakers in the West Virginia Senate want to put copies of the first Bible printed in revolutionary America in certain classrooms, but an effort by others to amend the bill to include the ...
A once-weekly injectable GIP/GLP-1 dual agonist conferred up to 22.5% weight loss at 48 weeks for adults with overweight or ...
Some lawmakers in the West Virginia Senate want to put copies of the first Bible printed in revolutionary America ...
One of the most thrilling, anchoring, humbling, inescapable aspects of traversing the streets of New Haven is to realize how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results